Minerva Surgical, Inc. (UTRS): Price and Financial Metrics

Minerva Surgical, Inc. (UTRS): $3.13

0.16 (-4.85%)

POWR Rating

Component Grades








Add UTRS to Watchlist
Sign Up

Industry: Medical - Services




#32 of 85

in industry

UTRS Price/Volume Stats

Current price $3.13 52-week high $17.67
Prev. close $3.29 52-week low $2.77
Day low $2.77 Volume 173,101
Day high $3.86 Avg. volume 98,872
50-day MA $4.35 Dividend yield N/A
200-day MA $5.11 Market Cap 555.84M

UTRS Stock Price Chart Interactive Chart >

UTRS Stock Summary

  • UTRS's went public 1.93 years ago, making it older than only 2.92% of listed US stocks we're tracking.
  • Over the past twelve months, UTRS has reported earnings growth of 1,040.17%, putting it ahead of 98.47% of US stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for UTRS comes in at -76.42% -- higher than that of just 7.65% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to MINERVA SURGICAL INC, a group of peers worth examining would be MLAB, THRN, POWL, STIM, and LPRO.
  • To dig deeper into the stock's financial statements, go to UTRS's page on browse-edgar?action=getcompany&CIK=0001452965.

UTRS Valuation Summary

  • In comparison to the median Healthcare stock, UTRS's price/earnings ratio is 103.37% lower, now standing at -0.9.
  • UTRS's price/sales ratio has moved down 6.1 over the prior 23 months.

Below are key valuation metrics over time for UTRS.

Stock Date P/S P/B P/E EV/EBIT
UTRS 2023-09-22 0.7 1.3 -0.9 -1.9
UTRS 2023-09-21 0.7 1.3 -0.9 -1.8
UTRS 2023-09-20 0.7 1.3 -0.9 -1.8
UTRS 2023-09-19 0.6 1.3 -0.9 -1.8
UTRS 2023-09-18 0.7 1.3 -0.9 -1.9
UTRS 2023-09-15 0.7 1.3 -0.9 -1.9

Minerva Surgical, Inc. (UTRS) Company Bio

Minerva Surgical Inc., a commercial-stage medical technology company, focuses on developing, manufacturing, and commercializing minimally invasive solutions to meet the uterine healthcare needs of women. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists across various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

UTRS Latest News Stream

Event/Time News Detail
Loading, please wait...

UTRS Latest Social Stream

Loading social stream, please wait...

View Full UTRS Social Stream

Latest UTRS News From Around the Web

Below are the latest news stories about MINERVA SURGICAL INC that investors may wish to consider to help them evaluate UTRS as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are worth keeping track of and we're helping with the biggest winners and losers for Wednesday morning!

William White on InvestorPlace | September 27, 2023

Minerva Surgical, Inc. (UTRS) Reports Q2 Loss, Misses Revenue Estimates

Minerva Surgical, Inc. (UTRS) delivered earnings and revenue surprises of 44.44% and 3.80%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 2, 2023

Minerva Surgical Reports Second Quarter 2023 Financial Results

SANTA CLARA, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women's health company focused on solutions to meet the distinct uterine healthcare needs of women, today reported second quarter financial results for the period ended June 30, 2023. Second Quarter Highlights: Reported revenue of $13.4 million in the second quarter of 2023, compared with revenue of $13.0 million in the second quarter of 2022Increased both Symphion an

Yahoo | August 2, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday!

William White on InvestorPlace | July 17, 2023

Investors in Minerva Surgical (NASDAQ:UTRS) from a year ago are still down 86%, even after 51% gain this past week

Minerva Surgical, Inc. ( NASDAQ:UTRS ) has rebounded strongly over the last week, with the share price soaring 51%. But...

Yahoo | May 25, 2023

Read More 'UTRS' Stories Here

UTRS Price Returns

1-mo -24.58%
3-mo N/A
6-mo -40.79%
1-year -80.32%
3-year N/A
5-year N/A
YTD -29.95%
2022 -95.65%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!